Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
Medtronic, a leading medical technology company, has received an expanded CE mark for its MiniMed 780G automated insulin delivery system in Europe. The new indication allows for broader use of the system, including in patients with Type 2 diabetes, during pregnancy, and in children as young as two years old.
The California life sciences sector continues to lead the nation in employment, despite a recent slowdown in growth. According to the California Life Sciences 2025 sector report, the state maintains approximately 345,000 jobs in the industry, showcasing its dominance in the biotech and pharmaceutical landscape.
In a significant development for the pharmaceutical industry, cancer startup Dispatch Bio has emerged from stealth mode with an impressive $216 million in initial funding. The company aims to tackle one of the most challenging areas in oncology: developing a universal treatment for solid tumors using a novel immunotherapy approach.
Tia, a women's health company, has announced a groundbreaking partnership with Talkspace to integrate mental health services into its comprehensive primary care model. This collaboration aims to address the unique mental health challenges women face throughout their lives, from adolescence to menopause and beyond.
Boston Scientific has emerged as a frontrunner in the rapidly evolving pulsed field ablation (PFA) market, while simultaneously navigating economic challenges with greater agility than initially anticipated. The company's latest financial results and strategic moves highlight the dynamic nature of the medical technology sector, as industry leaders adjust to regulatory and market pressures.
Flatiron Health, a subsidiary of pharmaceutical giant Roche, has announced a significant expansion of its international oncology network, tripling its size across the United Kingdom, Germany, and Japan over the past year. This growth marks a pivotal step in the company's mission to provide comprehensive real-world cancer data on a global scale.
A groundbreaking retrospective cohort study has uncovered potential neuroprotective effects of GLP-1 agonists, specifically Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. The study, published in JAMA Network Open, analyzed electronic health record data from over 60,800 adults aged 40 and above with type 2 diabetes and obesity who had initiated treatment with these drugs or other antidiabetic medications.
Tenet Healthcare, a major hospital operator, has raised its financial expectations for 2025 following strong second-quarter earnings. However, the company faces potential challenges from recent healthcare policy changes and market uncertainties.Tenet Healthcare has revised its 2025 financial guidance upward, now projecting revenue between $20.95 billion and $21.25 billion, with net income expected to range from $1.3 billion to $1.4 billion. This represents a significant increase from previous estimates of $20.6 billion to $21 billion in revenue and $1.1 billion to $1.2 billion in income.
French biotech company Abivax has reported positive Phase 3 results for its experimental ulcerative colitis medicine, obefazimod, causing the company's stock to surge over 500% on Wednesday. The drug, which represents a new approach in treating inflammatory bowel disease (IBD), has shown significant potential in a market projected to reach $30 billion by 2030.
Intuitive Surgical, the leader in robotic surgery, has reported robust financial results for the second quarter of 2025, while addressing various industry challenges and market dynamics. The company's performance reflects strong growth in its da Vinci robotic system placements and procedure volumes, despite ongoing macroeconomic pressures in key markets.
Sarepta Therapeutics faces a crisis as the FDA takes decisive action following patient deaths, while the pharmaceutical industry sees significant shifts in regulatory leadership and manufacturing strategies. These developments, coupled with recent drug rejections, signal a changing landscape for drug development and approval processes.
Boston Scientific, a leading medical technology company, has reported significant growth across multiple segments in the second quarter of 2025, prompting an increase in its financial forecasts for the remainder of the year. The company's performance was marked by notable advancements in medical surgical tools and cardiovascular technologies.
